

Registered in England and Wales  
Company Number 3963360

**THE ORCHID CANCER APPEAL  
'ORCHID'  
ANNUAL REPORT AND ACCOUNTS  
FOR THE YEAR ENDED 30 JUNE 2008  
Charity Number 1080540**

**THE ORCHID CANCER APPEAL**  
**INDEX TO THE ANNUAL REPORT AND ACCOUNTS**

	Page
Title page	1
Index to the Annual report and Accounts	2
Company information	3
Report of the Board of Trustees	4
Structure, Governance and Management	4
Objectives and Activities	5
Financial Review	12
Future Plans	13
Formal Statements	14
Auditor's Report	15
Statement of Financial Activities	16
Balance Sheet	17
Notes to the Financial Statement	18

# THE ORCHID CANCER APPEAL

## COMPANY INFORMATION

for the year ended 30 June 2008

---

Registered with the Charity Commission on 3<sup>rd</sup> May 2000

Company Limited by Guarantee

Charity Number 1080540

Incorporated in England Number 3963360

REGISTERED OFFICE	St. Bartholomew's Hospital London EC1A 7BE
BOARD OF TRUSTEES	Mr R S Broadhurst CBE (Chairman) Mr R J O Barton (Treasurer) His Honour G Boal QC The Rt Hon Lord Fellowes Mr C S Osborne Mr S Seymour Mr S Raby Mr D Badenoch Mr P Norman Professor RTD Oliver Mr R Lane (Appointed 10 March 2008) Ms D Selby (Appointed 9 June 2008)
CHIEF EXECUTIVE	Mr A J D Somerville
AUDITORS	Kingston Smith LLP Devonshire House 60 Goswell Road London EC1M 7AD
ACCOUNTANTS	JS2 Ltd 1 Crown Square Woking Surrey GU21 6HR
LEGAL ADVISORS	Farrer & Co 66 Lincoln's Inn Fields London WC2A 3LH
BANKERS	HSBC Plc. 20 Electric Parade George Lane South Woodford London E18 2LX  CAF Bank Ltd 25 Kings Hill Avenue Kings Hill West Malling Kent ME19 4JQ  COIF Charity Funds 80 Cheapside London EC2V 6DZ  Birmingham Midshires Pendeford Business Park Wobaston Road Wolverhampton WV9 5HZ

# THE ORCHID CANCER APPEAL

## REPORT OF THE TRUSTEES

for the year ended 30 June 2008

---

1. The Trustees who are also directors of the charitable company present their report for the period for the year ended 30 June 2008, together with the accounts covering the same period. Company Information is included as page 3.

### **STRUCTURE, GOVERNANCE AND MANAGEMENT**

2. Duly registered as a charity, The Orchid Cancer Appeal ('Orchid') is incorporated as a company, limited by guarantee, and governed by its Memorandum and Articles of Association. Its principal activity is to increase public awareness, and to improve and simplify the treatment of men's cancers, including the funding of research into diagnosis, prevention and treatment of male cancer.

3. Trustees are recruited on the recommendation of incumbent members of the Board, commensurate with the Chairman's aim to maintain a balanced composition. In line with this policy, two new trustees were elected during the year to provide a still broader range of expertise and experience. Applications from individuals seeking to become a Trustee will be considered as and when appropriate by the Board. The Board meets routinely four times every year, and at each Annual General Meeting, one third of the Trustees (or the nearest number thereto) retires from office in rotation, in order of longevity of appointment. If the ensuing vacancy is not filled, the retiring Trustee may be reappointed. Elections for the period under report are stated on page 3.

#### **Trustee training and induction**

4. On appointment, Trustees will receive an induction pack that includes the following:

- a copy of the Memorandum and Articles of Association
- a brief summary of the charity's history and significant events in its history
- the Annual Report for the last two years and the most recent sets of management accounts
- the minutes of the most recent meetings of the Board of Trustees and Scientific Advisory Board.
- Board papers outlining finance procedures, peer review, and grants & awards policy
- information to appraise them of the duties and responsibilities in accordance with App. 3 of ICSA guidance

In the absence of in-house provision, or an otherwise formalised programme of training, the Chief Executive alerts Trustees to opportunities that will increase their general understanding of charity and/or medical research issues. Trustees have availed themselves of these opportunities during the year.

#### **Structure, delegation and decision-making**

5. With its small organisational scale, Orchid does not require complex structural procedures. The staff continued to operate in an integrated fashion, affording the flexibility needed to accommodate peaks of activity across the fundraising disciplines. During the year, staff numbers increased to 7, following the recruitment of an experienced fundraiser and an assistant to manage the increasing load of supporter-led and internally organised events. Temporary and volunteer personnel were engaged for specific tasks to ensure a balanced approach to managing administration, the awareness campaign, and fundraising. The Board's endorsement of a structural blueprint aimed at developing the charity's business capacity resulted in the appointment, in June 2008, of a Director of Marketing whose previous track record in three well-known medical charities has provided a critical professional input in this key area.

The decision-making process operates as follows:

- At the strategic level, the Board of Trustees regularly reviews Orchid's direction in the wider context of medical charities, requiring the Chief Executive to identify relevant key issues and present options for its consideration. Due governance remains a key requirement.
- The Finance and General Purpose Committee, comprising the Honorary Treasurer, Mr J Barton, as Chair, Mr R Broadhurst and Mr C Osborne, continues to supervise Orchid's financial and general management, and presents a report to the Board each quarter.
- The Board plans to augment the committee structure by establishing a number of sub-committees to enable Trustees to apply their expertise and interest more effectively in support of the charity's operational activity. These will be formed in the first half of 2008/09

# THE ORCHID CANCER APPEAL

## REPORT OF THE TRUSTEES

for the year ended 30 June 2008

---

- At the operational level, the Board delegates the day-to-day running of the charity to the Chief Executive, requiring him to deliver every aspect of governance, planning and performance in accordance with the agreed strategic direction, and the resulting Business Plan devised to implement it. In normal circumstances, the Board is kept apprised of personnel/budgetary issues and achievement against fundraising targets, together with progress of research and awareness activity.

### Peer Review

6. Given the importance of expert independent peer review in validating applications for research grants and the verification of outcomes, the Scientific Advisory Board (SAB) provides the Board of Trustees with the necessary degree of objectivity as to the quality, value for money and efficiency of research that the charity currently funds or may consider funding. In accordance with best practice, all SAB members have been approached during the year to establish their continued willingness to serve, and additional members have been enrolled, notably two from Europe, to ensure that the SAB's opinion includes those from outside the UK research community. The SAB's fourth report was presented to the Board of Trustees in March 2008 by its Chairman, Professor Norman Maitland, and again provided essential guidance to the Board when it considered its award of future research grants for the financial year 2008/09. It was particularly gratifying that the report was highly complimentary about the results of the key research disciplines, and congratulated three programme leaders on the results achieved in the previous year. The Board wishes to thank the SAB members for giving their time and expertise to the charity, and to Professor Maitland, in particular, for providing advice to the less experienced programme leaders in relation to their work.

### Risk management

7. The Board of Trustees has established the functional areas in which the realisation of risks would have a significant effect on the effectiveness and sustainability of the charity. A matrix is used to identify individual risks in terms of severity of impact and likelihood of occurrence, together with the monitoring process and the action to be taken in that eventuality. The Board routinely, and not less than annually, reviews the matrix to ensure that it reflects the dynamic nature of the business, agrees the major risks, and directs the Chief Executive as to the priorities and action to be taken to mitigate or remove them.

## OBJECTIVES AND ACTIVITIES

8. The object for which Orchid is established is the promotion of research into, and education about, the diagnosis and treatment of genital cancer and related conditions.

### Strategic Review

9. At its Away Day in November 2006 to examine Orchid's future strategy, the Board agreed the charity's mission as follows:

*Orchid exists to save men's lives from testicular, prostate and penile cancers by pioneering research and promoting awareness.*

The charity's vision was similarly refreshed as follows:

*To promote greater knowledge and awareness about male specific cancers by:*

- *funding integrated scientific and medical research into prevention, diagnosis and treatment of these diseases, and*
  - *providing eye-catching, easy to understand information about them to men and women throughout the UK, thereby helping to ensure a better quality of life or even life itself for those affected.*
- In doing so, Orchid aims to become the leading UK male cancer charity.*

10. Having thus re-validated the charity's aims and objectives, the Board engaged, on a part-time basis, an experienced charity senior executive to work with Orchid's Chief Executive to evaluate the organisation needed to deliver the mission in the most cost-effective and cause-effective way. After considering the options presented, the preferred structural blueprint was endorsed by the Board, and its incremental implementation approved, the most important component of which was the engagement of a Director of Marketing and Fundraising shortly after the year-end. That appointee has since refined the structure in the light of current circumstances, and the first of two new positions are in the process of being recruited.

11. In parallel, steps commenced to secure a suitably qualified individual to act as the charity's medical champion and give necessary focus, in particular, to the research it funds. This coincided with a proposal from the Barts and London School of Medicine and the NHS Trust to help it to establish a Chair of Male Genito-

## THE ORCHID CANCER APPEAL

### REPORT OF THE TRUSTEES

for the year ended 30 June 2008

---

Urinary Oncology, effectively to replace the post that lapsed when Professor Oliver retired. The rationale was that, having been instrumental through its Male Cancer Clinical Trials Unit in the establishment of the Barts and London Experimental Cancer Medicine Centre (which was officially opened in March 2008), it would be logical and mutually beneficial for the charity to fund the new Chair, in whole or in part.

12. In accordance with the Board's tenet that charities should collaborate to the maximum extent possible, and mindful that the likely total cost exceeded what it considered prudent in view of its extant support of research, an approach was made to the Barts and London Charity (BLC) to explore the possibility of a collaborative funding arrangement of the Chair. In doing so, the Board recognised the implications of such an approach, for example in relation to the joint naming of the Chair and the extent to which the incumbent would be able to champion the charity's work. Having received an encouraging response in principle from BLC, the Board considered a joint grant application from the Bart's and London School of Medicine and the NHS Trust, and approved a grant of £500k over 3 years to establish, subject to a similar grant award by the BLC. This was duly approved by the latter's Board in November 2008. Work to establish the post and its infrastructure will be monitored, with the aim of balancing Orchid's interests in the Chair-holder's with those of the BLC and the institutions involved.

#### Operating context

13. 2007/08 was a year in which weaker growth in the first half was offset by strong performance in the 3<sup>rd</sup> and 4<sup>th</sup> Quarters. This was largely due to the reduction in operating capacity between July and November 2007 following the departure of one Events Manager, the arrival of the replacement and the recruitment of an assistant. As events play a significant role in the enhancing the charity's profile, the importance of responding to supporters who arrange their own activities, as well as efficiently managing Orchid's own or procured events, are vital in both fundraising, promotional and awareness raising terms. The availability of pro bono services are equally important in reducing the in-house or paid-for capacity, although delays in the production of a top quality material reflected the difficulties of bringing such diverse elements together without contractual leverage. This delayed the inception of a range of fundraising initiatives which precluded achievement of some of the more challenging income targets.

14. Looking ahead, the Board is fully aware of the very testing financial climate that currently prevails, and is realistic as to the potential consequences for fundraising. While some opinion holds that smaller well-found charities may find it easier to navigate the undoubted pressure than those with greater infrastructure to service, there can be no doubt that it will be more difficult to secure funds in a highly competitive sector. A key consideration in this respect is the impact of the receipt this year of the last major donation in a series from one of the charity's earliest benefactors. To this end, a campaign to engage with high net-worth individuals, whether as individuals or through their connections with corporates and/or grant-making trusts, has been instigated.

15. In pursuit of maximising progress in the male cancer field through partnership, the charity continues to demonstrate its commitment to collaborate with other representative groups. Its most significant involvement is through its work with the Prostate Cancer Charter for Action, an influential collaborative of 24 not-for-profit and professional organisations, whose lobbying has resulted in important advances in prostate cancer by the Department of Health (DH). As well as being a Signatory Charity, Orchid's CEO plays a leading role in its organisation and outputs, in his roles as a member of the Charter's Steering Group, and Specialist Nurses Working Group. This latter Group this year published a highly influential report on the need substantially to increase the number of dedicated specialist prostate cancer nurses to bring nursing provision for this disease up the level in place for breast cancer.

16. Orchid is also playing a full part in Cancer 52, an equivalent collaborative concerned with less common cancers (ie all those except prostate, lung, breast and bowel disease) that together account for around 52% of all cancer deaths in the UK. Orchid's CEO has chaired its strategy meeting and is a member of its Coordination Group and the Improving Outcomes Guidance Review group. He will also represent it on the National Cancer Survivorship Initiative Research work stream, set up under the auspices of the NCRI as a consequence of the Cancer Reform Strategy. Other areas of involvement include the Cancer Campaigning Group and the Men's Health Forum.

17. It is essential, when funding scientific and medical research, to ensure the quality and value for money of the work undertaken, in order to meet the standards of governance laid down by academic institutions and the Department of Health.

# THE ORCHID CANCER APPEAL

## REPORT OF THE TRUSTEES

for the year ended 30 June 2008

---

### Objectives

18. The objectives of the charity are to raise funds for scientific and clinical research into prostate, testicular, and penile cancers, and to promote awareness and education about these diseases.

- **Research.** Orchid aims to improve diagnosis and treatment of men with gender-specific forms of cancer, by investigating novel hypotheses that cross the conventional medical and scientific boundaries, commonly known as 'translational' research, which seeks to apply successful laboratory findings in a clinical setting for the ultimate benefit of patients (colloquially known as 'bench-top to bedside'). The charity funded 4 areas of research: basic science in molecular therapeutics, carcinogenesis, histopathology, and clinical trials. Through its support, Orchid seeks to promote improved treatment from intermittent hormone therapy and the novel combinations/sequencing of existing drugs, to identify the role of cell signalling, and stem cells in male cancer development, and to exploit historical and fresh tissue bank material for comparison purposes.

- **Awareness.** Early diagnosis is the key to successful treatment of cancer at the earliest stage of the disease, and thus to the chances of survival and the ensuing quality of life. Orchid's eye-catching and informative awareness material seeks to help men, and the women in their lives, understand these gender-specific diseases, detect potential symptoms early, and be aware of the implications of any subsequent treatment.

### Goals for FY 07/08

19. The goals for 2007/08 are listed below annotated with the level of achievement:

- *Implement the restructuring plan for the organisation to provide the platform from which to increase the income and outputs of the charity.*
  - Achieved. Implementation of the new organisation has commenced with the appointment of the Director of Marketing and an Events Fundraising Assistant. Recruitment of the posts in the revalidated structure will continue in 2008/09.
- *Revitalise efforts to secure substantial support, ideally for more than one year, from potential major donors (on a personal, trustee or corporate basis), with a target income figure of £100,000 in 2007/08.*
  - Ongoing. Following delays in the production of essential resources to accompany approaches, a high profile reception has been planned in 2008 to secure interest and support.
- *Enlist medical champion to act as advocate for the Charity's work.*
  - Ongoing. Steps to approach potential candidates individually were deferred pending the outcome of the Chair of Oncology proposal.
- *Continue to refine the focus of support to research activity, in line with advice from the SAB, to ensure the optimum application of grant awards, where appropriate in collaboration with Barts and the London School of Medicine/NHS Trust.*
  - Achieved. The research grant awards for 2008/09 reflected feedback from the SAB leading to support of more productive work-streams. The programme leaders of the clinical and molecular therapeutics programmes were successful in securing their own track tenure, through Barts & the London, and an MRC grant respectively, thus safeguarding their personal positions within the School of Medicine, and vindicating the Board's decision to cease funding thereof in 2006/07. Having held the 2008/09 grant award for the carcinogenesis programme in reserve pending action in response to the SAB's previous comments, the grant award was revoked. While regrettable, this reflects the rigorous approach that the Board seeks to apply to its support of research. See Research Report below for more detail.
- *Examine the scope to fund, fully or jointly, a Chair of Medical Oncology in the Barts & London School of Medicine.*
  - Achieved/Ongoing. The Board considered a grant application to co-fund a Chair of Male Genito-Urinary Oncology, and approved an award subject to its conditions, and an equivalent grant by the Barts and The London Charity, (which was made after the year end).
- *Monitor developments in relation to the AMRC's policy on membership for single institution research funding and, depending on the outcome, negotiate full or associate membership as appropriate.*
  - Ongoing. The AMRC policy has been reissued and it is apparent that Orchid's grant-making procedures are broadly consistent therewith; the steps needed to establish the precise requirements for association/membership are awaited.

## THE ORCHID CANCER APPEAL

### REPORT OF THE TRUSTEES

for the year ended 30 June 2008

- *Promote a new range of updated information leaflets, and increase the distribution of awareness material by 10% from 2006/07 levels.*
  - Achieved. A copy of Orchid's award winning awareness DVD has been sent to every Young Offender and Excluded Pupil Centre in the UK, and also made available, free to every School Nurse through a promotional campaign in professional nursing publications.
- *Conduct survey of schools to elicit feedback on awareness DVD and promote support of the charity.*
  - Achieved. The results are under evaluation, together with a further survey of School Nurses.
- *Secure major corporate partner to utilise awareness material throughout its business, whilst encouraging staff fundraising activity.*
  - Ongoing. The Post Office participated in the launch of a nationwide awareness campaign "Checked Out" and several high street retailers have continued to support Orchid during the year.
- *Consolidate the charity's presence in cycling and running events, and examine the opportunity to extend its profile into other sport/challenge related fundraising activity.*
  - Achieved. The OrchidCycle Series, including the charity's internally organised event in Essex proved highly successful and generated greater returns than the previous year. Orchid's presence in the World Major Marathons produced excellent returns, and further national fun run events were added to the portfolio during the year.

#### Research

20. Orchid-funded research has made significant strides in the past year. Having refined its support as a result of previous commentary for the SAB, its 4<sup>th</sup> Annual Report reflected a general opinion that much progressive work had been carried out, with the clinical research programme being singled out as the outstanding success, and worthy of praise this year, in view of its formidable output, in some excellent journals, and with a considerable impact.

In 2008, Professor Oliver received well deserved credit for his work to show that a single dosage regime of carboplatin prevents testis cancer returning after initial surgery for this disease, when he presented the plenary session at ASCO 2008, the largest international cancer forum, with over 30,000 delegates. His treatment has changed the way testis cancer is treated world-wide, and much of the early work was conducted in the Clinical Trials Unit. Having demonstrated its importance in discovering new cancer treatments, the CTU's current pipeline is strong and hopes to achieve similar breakthroughs in future.

Clinical Research (Dr Jonathan Shamash, programme leader; Dr Tom Powles - Clinical Senior Lecturers)

#### Summary

The main focus of the clinical research in 2008 has been to take forward the positive results published in 2007, by opening new studies in prostate and testis cancer to answer questions raised by earlier findings.

The introduction of a risk-stratified approach for relapsed testicular cancer based has allowed patients to be offered a short intensive therapy with no adverse risk factors. It seems that the outcome for such patients is very favourable with a cure rate of over 80%. The remainder, who do less well represent a difficult subgroup and a new study (GAMIO) is due to start in 2008 for them.

In prostate cancer, the observation that hormonal therapy may work well following failure of chemotherapy, and that early prediction of those patients who will gain prolonged benefit from diethylstilbestrol and corticosteroids, has been the basis of the CTU's achievements in the past year.

6 publications have been achieved in 2008, including first authorship in the Journal of Clinical Oncology, British Journal of Cancer, and Annals of Oncology.

#### Results in 2008

**Major Achievement.** The completion of the DADAS trail, only the second such randomised multi-centre phase III study, involving over 200 patients with advanced hormone resistant prostate cancer, answered important questions about optimal treatment. Led by Dr Shamash, it was chosen as a national study, which assisted its timely conclusion, the data from which has been analysed ready for publication in 2009. Its robust, interesting, and reproducible results will give doctors and patients useful information in this difficult situation.

## THE ORCHID CANCER APPEAL

### REPORT OF THE TRUSTEES

for the year ended 30 June 2008

---

#### Other areas of development:

- taking forward published work in relapsed testis cancer through a new trial starting in late 2008; known as GAMIO, it investigates 2 promising new drugs in this setting (irinotecan and oxaliplatin) and will be the major focus of our testis cancer clinical trials work.
- further investigation of intermittent hormone therapy in advanced prostate cancer by giving chemotherapy in the absence of hormone therapy. A randomised multi-centre trial, this will take over from the recently completed DADAS study as the major focus of our prostate cancer work.
- investigation over 5 years into the role of immune suppression in the development of testis and prostate cancer. An article has been accepted by the prestigious Journal of Clinical Oncology.
- the conclusion that the long term risks of osteoporosis in patients treated for testis cancer are not as great as originally feared, even after chemotherapy, is due to be published in 2008, which was only possible because of our policy of prolonged follow-up for this group of patients.

#### Other studies underway

- **TE3 - Patients with good risk but advanced testicular cancer.** This multi-centre NCRN approved study investigates bleomycin infusions over 3 days compared to bleomycin bolus doses in patients with metastatic testis cancer. Recruiting well, it should finish within 2 years.
- **Single agent carboplatin in patients with good risk metastatic seminoma.** Interim analysis of the single agent carboplatin AUC10 study has shown promising results, justifying the move to full recruitment.
- **PPAR in prostate cancer.** This study investigates whether the widely available but as yet untried combination of drugs used to treat diabetes (rosiglitazone) and lower lipids (fenofibrate), may induce maturation and stabilisation of prostate cancer. Recruiting patients well, the treatment seems to have extremely few side effects
- **Melphalan and whole blood stem cell re-infusion in castration-resistant prostate cancer.** In this study we are assessing the role of melphalan chemotherapy in patients with advanced prostate cancer. This drug is normally limited by its effect on the bone marrow and can normally be given every 4-6 weeks. By giving large doses of growth factors and collecting blood prior to chemotherapy and returning it to the patient 12- 25 hours after chemotherapy, melphalan can be given every 2 weeks. We are also quantifying/analysing circulating tumour cells as these have been shown to be both prognostic and predictive of response to chemotherapy in prostate cancer.

#### Studies due to open in 2008/2009

- **Testis cancer GAMIO (novel protocol for patients with poor prognosis, relapsed germ-cell tumours)** This study will exploit the Anglian Testis Cancer group, one of the largest collaboratives in testis cancer in the world, supported by Orchid. 47 patients with relapsed testis cancer will be recruited over a 4 year period, and 2 new drugs used which were shown to be highly effective in 2007.
- **CASPER intermittent hormone therapy during chemotherapy for castrate resistant prostate cancer.** This randomised multi-centre study will discover if it is safe to stop hormone therapy during chemotherapy in hormone resistant prostate cancer. This form of intermittent hormone therapy is novel and will give insight into why patients become resistant to hormones.

#### Translation studies to link the laboratory with the clinic.

We have embarked on a pilot study investigation the significance of cancer cells, measured from the blood, in patients with prostate cancer. These circulating cancer cells can be found in patients with advanced disease. Our pilot data, along with work from others, suggests they may be important in predicting which patients respond to which type of therapy. This is especially important in hormone resistant prostate cancer because tests like X-ray and PSA are not particularly useful in this setting. It is our intention to take the measurement and characterisation of these circulating cancer cells in cancer forward in the prostate cancer studies described above.

In testis cancer we will exploit the new PET/CT scanner at Barts which can give information about not just the size of the cancers but also the activity of the cancer cells. This is because cancer cells use more glucose than normal cells, and we can measure how much glucose is taken up by these cancer cells. We plan to see if early changes to the glucose uptake of the cancers correlate with outcome to specific treatment.

# THE ORCHID CANCER APPEAL

## REPORT OF THE TRUSTEES

for the year ended 30 June 2008

---

### Data collection studies.

We have successfully collaborated with the Chelsea and Westminster Hospital and the Thames Cancer Registry to calculate the risk of testis and prostate cancer with prolonged immune suppression. The results are striking in that immune suppression results in an initial increased risk of testis cancer, however over time this risk reduces back to normal. This is in contrast to prostate cancer where we show an initial decreased risk which remains low over time. This work was accepted for publication by the Journal of Clinical Oncology.

### Plans for 2009

- To investigate if prostate cancer metastasised more quickly in the young, collaborating with the British Urology Group.
- To study prognostic factors associated with relapsed testis cancer, collaborating with Prof Bayer in Berlin.
- Assess the toxicity of chemotherapy in patients over 50 treated with testis cancer, collaborating with the Danish Cancer Database.

### Scientific research

#### Histopathology Programme (Dr Dan Berney)

Histopathology research, involves tests on surplus tissue left over after surgery, so establish better diagnosis and treatment of diseases.

The histopathology or 'Tissue' group has had a highly successful 2007/08 with the publication of over 10 papers and reviews, indicative of the quantity and quality of its output in this key discipline. Much work has been conducted in collaboration with the other Orchid funded research programmes, providing tissue and pathological support:

**Prostate:** Apart from 8 published papers, the group has expanded the trans-Atlantic collaboration with an external grant to fund an investigation into early prostate cancer. We have 2000 patients in our programme so far, and hope to double this in the next 4 years.

**Testis:** Work on testis cancers in the elderly was published in an American journal, Modern Pathology, as well as a prestigious review article in Histopathology called 'Ten Testicular Trapdoors!' He was an invited speaker on testis cancer at the International Association of Pathology.

**Penis:** Our first paper on penile cancer was published this year. The Orchid Tissue Bank has the largest collection of penile cancers in a tissue array in Europe, and has presented 5 posters on the work, with papers to follow.

#### Molecular Therapeutics Programme (Dr Yong Jie Lu, Senior Lecturer)

This programme focuses on identifying genetic mechanisms of cancer development and chemo-resistance, and attempting to translate them into new therapies.

**Testis:** Following Dr Lu's previous work using micro-arrays to screen testicular germ cell tumours across the genome spectrum, for genes involved in chemo-resistance, a number of genes were selected and investigated for their potential in re-sensitising the resistant cancer cells. Previously, this team had proved that switching off one specific gene increases cell death when treated with the therapeutic drug cisplatin. This year, more excitingly, they have identified one gene as the main cause of testicular germ cell cisplatin resistance. This gene is essential in controlling cell growth and in many human cancers it is over-active, which leads to the cancer cells responding badly to therapeutics. By switching this gene off, the cancer cells can be killed much more easily.

**Prostate:** Following the development of a novel genetic study approach to identify genetic biomarkers for cancer diagnosis and outcome prediction, Dr Lu's team has used it to identify several new genetic defects in prostate cancer. His team also demonstrated that genomic instability is the main cause of genetic alterations in cancer development. The gene, which was previously detected by this research team as frequently absent in TGCTs, is now also commonly found to be 'switched off' in prostate cancer. The tumour suppressor role of this gene is currently under further investigation. All these discoveries will eventually lead to an improved cancer treatment strategy.

Achievements this year have seen papers published in the Asian Journal of Andrology, Cancer Letter, and Genes Chromosomes Cancer; others have been submitted, or are in preparation, for publication.

# THE ORCHID CANCER APPEAL

## REPORT OF THE TRUSTEES

for the year ended 30 June 2008

---

### Summary

After a number of years in which preparatory and underpinning work was carried out, together – in the case of the clinical trial group – with recruiting patients into trials, an impressive number of results have been forthcoming that have received national and international recognition. This provides an important platform for future development, with continued emphasis on translational work, and should lead to better treatment as well as offering significant potential for improving survival and quality of life for male cancer patients.

### Fundraising

21. Income in 2007/08 again benefited from the generosity of a major benefactor who has been supporting the charity since 2001, and who made the final donation in his sequence of pledges in the year reported. In recognition of the need to increase the breadth and depth of funds from other sources, the fundraising targets set for the year aimed at replacing a proportion of the major donation that would not be repeated in future. Although a key fundraising position was gapped during the first four months of the year, which coincided with the 'retirement' of a long term volunteer from day to day activity, income was resilient, at £1,301,428 (2006/07: £1,295,409), exceeding the annual budget (£1,256,630). This achievement, coupled with a lower than budgeted level of expenditure, meant that reserves increased by the amount originally anticipated. The following information summarises the various disciplines:

- Profile. The charity continues to benefit from its growing profile, as evinced from its national awareness campaign, the visibility afforded by some notable corporate partnerships and the burgeoning supporter base, which has resulted in an increase in the income of unsolicited fundraising activities, particularly through from supporter-organised events.
- Direct Mail. As in earlier years, it was not possible to revitalise a formal Friends of Orchid scheme, owing to the pressure of other fundraising priorities, and the need to revalidate the supporter database. However, a pilot mailing to some 200 supporters at the very end of the previous financial year elicited a pleasing return, and has resulted in a more substantial direct mailing initiative, again targeted at known supporters, in 2008/09. The poor return on investment inherent in large scale direct mailing on a nationwide basis has led for this fundraising technique to be deferred.
- Events. Orchid has maintained its investment in places and promotion in the London, New York, Chicago and Berlin World Marathon Majors, and secured a healthy return on investment, despite finding it difficult, in common with other charities, to fill places in the latter two venues. For next year, more emphasis will be put on targeting own place runners, whilst extending our presence in the new running events, Run to the Beat and The Royal Parks as well as in the Great North and South Runs.
- Our eighth annual charity bike ride, OrchidCycle Essex, was bigger and better than its predecessors, while commercially organised rides in Holland and the New Forest, with over 1000 participants, were equally successful. This year saw a single venue for our awareness/fund-raising event, Men in Pants in Paternoster Square, where an unusually sunny day added to the lively atmosphere, and certainly brought the charity and our cause to the attention of many.
- Other events, organised by new and established supporters, were especially welcome. Among the highlights were a Dinner hosted by the England rugby player Jason Leonard, and three Balls held in London, Windsor and Huddersfield between them raising over £100,000. Golf Days have been held at the Loch Lomond, Ilford, Cottesmore, and Lords Golf and Country Club
- While 2007/08 did not include a repeat of the extreme sporting efforts of recent years, two supporters are preparing to row across the Indian Ocean in aid of Orchid in spring, while the charity is arranging a Kilimanjaro trek challenge through an experienced travel company.
- Corporate Relations. Productive links with Paperchase and Green's of St James' have been maintained this year, while Austin Reed extended its association with Orchid as its chosen charity for a third year. We are very grateful to all of them for their continued support. SCA Hygiene has supported Orchid throughout the British Superbikes Season with its Tena for Men product range, while Armani and Crombie have both held seasonal collection launches in our aid. The high street retailer, NEXT, selected Orchid as the recipient of fundraising from its Annual Golf Day. Matched giving schemes remain an invaluable source of income and we appreciate the numerous companies that operate them to encourage their staff to our ultimate benefit. The continued value of Charterhouse through its pro bono printing, and design by St Cross, cannot be underestimated, whilst the long time in-kind donation from Goodman Baylis has drawn to a close following the sale of the company. The Board is immensely grateful for their generosity. Most recently, Hampton Printers has produced a stylish Case for Support brochure.

# THE ORCHID CANCER APPEAL

## REPORT OF THE TRUSTEES

for the year ended 30 June 2008

- Trust and Foundations Income from this source has remained steady, despite the considerable increase in the competition for funds and the number of grant-making bodies which prefer to make awards as a result of personal knowledge of, or particular interest in, a specific field. At the end of the year, an analysis was started to identify the opportunities available to increase fundraising effectiveness in this area, and steps put in place to refine the application process, and capitalise on networks/contacts at Trustee level, to access organisations that do not accept unsolicited requests.

### Summary

2007/08 has seen previous annual improvements in Orchid's fundraising from the general public consolidated, despite a temporary reduction in staff capacity. Returns received voluntarily and those secured from events using the charities resources, have risen compensating for more static income from other fundraising areas. Given the 2006/07 comparator, the income achieved in 2007/08 is pleasing, but the current financial difficulties make the outlook for maintaining this progress less certain. The fundraising environment will become even more competitive, requiring Orchid to market and promote itself effectively in order to have its cause recognised and supported, which the organisational blueprint approved during the year is designed to achieve.

## FINANCIAL REVIEW

### Investment Policy

22. The Trustee's policy is to hold funds on deposit with HSBC, Birmingham Midshires and the Charity Aid Foundation and COIF Charity banks.

### Results for the Year

23. Incoming resources for the period totalled £1,301,428 (2006/07: £1,295,409). After a total expenditure of £921,442 (2006/07: £966,584), the period's activities show a net surplus of £379,986 (2006/07: £328,825). Included in the total expenditure in 2007/08 is the award of the research grant of £530,025 for work to be carried out in 2009/10, which represented the charity's liability for that commitment.

### Reserves Policy

24. Designated reserves are funds that have been earmarked by the trustees for future expenditure on the objectives of the Charity, and at the end of the year the Trustees had designated £1,250,000 towards future research grant awards. The increase in the level of funds retained reflects the Trustees aspiration to co-fund a Chair of Oncology in the Barts & London School of Medicine, which will require a commitment of £500k in 2008/09, while ensuring that programmes currently funded will continue to be supported beyond the current commitment, subject to the feedback from the independent peer review process.

25. Free reserves are distinct from funds that have been earmarked or 'designated' for future expenditure on the objectives of the Charity, but for which legal liability has not yet been accepted. They must be maintained at a level which ensures that the Charity's core activity of funding research and awareness during a period of unforeseen difficulty and a proportion must be in a readily realisable form. The calculation of the required level of reserves is an integral part of the Charity's planning, budgeting and forecast cycle. It should take into account:

- risks associated with each income and expenditure stream differing from that budgeted
- planned activity level
- organisational commitments.

26. The available reserves net of tangible fixed assets are approximately £359,406 (2006/07: £259,420). This represents approximately 9 months of operating costs at current levels and provides resources to fund the organisational restructure recently agreed by the Board. This is above and beyond activity to which the charity is legally committed, or funds that have been otherwise specifically restricted or designated. In calculating the sum set aside for this purpose, the Trustees have noted that income in 2008/09 will be affected by the end, this year, of a sequence of major donations, for which it is unrealistic to expect other fundraising activity to compensate in full. Moreover, the current financial crisis has a potentially severe adverse impact on the prospects for income generation in the near to medium term, and thus the Trustees consider the increased level of reserves as a prudent response to these risks.

## THE ORCHID CANCER APPEAL

### REPORT OF THE TRUSTEES

for the year ended 30 June 2008

---

#### FUTURE PLANS

27. **Structural Development.** As presaged at para 10, implementation of the Board's policy to enhance the charity's capacity by increasing the number of staff to realise the charity's fundraising potential, has commenced. The new Director of Marketing, working closely with the Chief Executive, has refined the organisation and the resulting personnel changes were approved at the Sept 08 Board meeting. It was accepted that there will be an inevitable lag in securing the return on the initial investment of new staff, but the Board agreed that the alternative would mean that the charity would stand still, if not lose ground, in the competitive sector.

28. While Orchid's priority output will remain medical and scientific research, and pursuing its organisational changes, a key objective during the year will be to enhance Orchid's awareness campaign into more active support for men and their families affected by male cancer, thereby sustaining the core supporter base and attracting more potential supporters by extending Orchid's reach. As a result, the following goals have been identified for 2008/09:

- Support research activity, as advised by the SAB, to ensure the quality and value for money of the translational scientific and clinical programmes, in collaboration with Barts and the London School of Medicine/NHS Trust.
- Implement the co-funding of the Chair of Male Genito-Urinary Oncology in the ECMC, with the BLC.
- Secure funding to establish a dedicated telephone service or equivalent facilities to provide information and support in relation to penile cancer.
- Secure funding to recruit a research information officer, to conduct research grant and SAB administration, and act as the charity's spokesperson in relation to matters of research and awareness with the general public/media etc.
- Recruit the necessary personnel to realise the revised organisation to enable Orchid to generate the required level of income and charitable activity.
- Increase the distribution of information and awareness material by 10% from 2007/08 levels, as part of enhancing our audience reach.
- Develop the Orchid website to meet and deliver the needs of a range of stakeholders.
- Secure support to enable two new research projects.
- Build the charity's presence in cycling and running events, while rigorously scrutinising the return on investment, and conduct a successful Kilimanjaro challenge trek.
- Re-engage with the AMRC to establish the protocols involved with membership for single institution research funding and, depending on the outcome, negotiate full or associate membership as appropriate.

# THE ORCHID CANCER APPEAL

## REPORT OF THE TRUSTEES

for the year ended 30 June 2008

---

### FORMAL STATEMENTS

#### Statement of Trustees' Responsibilities

29. The Trustees are responsible for preparing the Annual Report and the financial statements in accordance with applicable law and regulations.

Company law requires the Trustees to prepare financial statements for each financial year in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). The financial statements are required by law to give a true and fair view of the state of affairs of the charity and of the income and expenditure of the charity for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- make judgments and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business.

The Trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Companies Act 1985. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

#### Auditors' Information

30. So far as each of the directors at the time the trustees' report is approved is aware:

- a) there is no relevant information of which the auditors are unaware; and
- b) they have taken all relevant steps they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditors are aware of that information.

31. The auditors, Kingston Smith LLP, have been authorised for appointment in accordance with Section 385 of the Companies Act 1985.

Kingston Smith LLP has indicated their willingness to continue in office and in accordance with the provisions of the Companies Act, it is proposed that they be re-appointed auditors for the ensuing year.

32. The accounts have been prepared in accordance with the provisions of the Companies Act 1985 Part VII relating to small companies, the Charities Statement of Recommended Practice (SORP 2005) and the Memorandum and Articles of Association of the Company.  
Signed on behalf of the Trustees.



8 December 2008

---

**R S Broadhurst Esq CBE**  
Chairman of Trustees

# THE ORCHID CANCER APPEAL

## AUDITORS REPORT

For the year ended 30 June 2008

We have audited the financial statements of the Orchid Cancer Appeal for the year ended 30<sup>th</sup> June 2008 which comprise the Statement of Financial Activities, the Balance Sheet and the related notes. These financial statements have been prepared under the historical cost convention and the accounting policies set out therein.

The report is made solely to the company's members, as a body, in accordance with Section 235 of the Companies Act 1985. Our audit work has been undertaken for no purpose other than to draw to the attention of the charitable company's members those matters which we are required to include in an auditor's report addressed to them. To the fullest extent permitted by law, we do not accept or assume responsibility to any party other than the charitable company and charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed.

### Respective Responsibilities of the Trustees and Auditors

The trustees' (who are also the directors of the Orchid Cancer Appeal for the purposes of company law) responsibilities for preparing the Trustees' Annual Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice) are set out in the Statement of Trustees' Responsibilities.

Our responsibility is to audit the financial statements in accordance with relevant legal and regulatory requirements and International Standards on Auditing (UK and Ireland).

We report to you our opinion as to whether the financial statements give a true and fair view and are properly prepared in accordance with the Companies Act 1985. We also report to you if, in our opinion, the charitable company has not kept proper accounting records, if we have not received all the information and explanations we require for our audit, or if information specified by law regarding trustees' remuneration and other transactions is not disclosed.

We read the Trustees' Annual Report and report to you our opinion on whether it is consistent with the financial statements. We consider the implications for our report if we become aware of any apparent misstatements or material inconsistencies with the financial statements.

### Basis of Audit Opinion


We conducted our audit in accordance with International Standards on Auditing (UK and Ireland) issued by the Auditing Practice Board. An audit includes examination, on a test basis, of evidence relevant to the amounts and disclosures in the financial statement. It also includes an assessment of the significant estimates and judgements made by the trustees in the preparation of the financial statements, and of whether the accounting policies are appropriate to the charitable company's circumstances, consistently applied and adequately disclosed.

We planned and performed our audit so as to obtain all the information and explanations which we considered necessary in order to provide us with sufficient evidence to give reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or other irregularity or error. In forming our opinion we also evaluated the overall adequacy of the presentation of information in the financial statements.

### Opinion

In our opinion:

- the financial statements give a true and fair view, in accordance with the United Kingdom Generally Accepted Accounting Practice, of the state of the charitable company's affairs as at 30 June 2008 and of its incoming resources and application of resources, including the income and expenditure of the charitable company for the year then ended; and
- the financial statements have been properly prepared in accordance with the Companies Act 1985.
- the information given in the Trustees' Annual Report is consistent with the financial statements.



Devonshire House  
60 Goswell Road  
London EC1M 7AD

22 January 2009

Kingston Smith LLP  
Chartered Accountants and  
Registered Auditors

**THE ORCHID CANCER APPEAL**

**STATEMENT OF FINANCIAL ACTIVITIES**

For the year ended 30 June 2008

	Note	Unrestricted Funds £	Restricted Funds £	TOTAL 2008 £	TOTAL 2007 £
<b>INCOMING RESOURCES</b>					
<b>Incoming Resources from Generate Funds</b>					
Voluntary Income		622,374	16,601	638,975	959,494
Events Income		478,123	-	478,123	183,183
Other Income		32,207	-	32,207	27,449
Deposit Account Interest		152,123	-	152,123	125,283
<b>Total Incoming Resources</b>		<b>1,284,827</b>	<b>16,601</b>	<b>1,301,428</b>	<b>1,295,409</b>
<b>RESOURCES EXPENDED</b>					
<b>Cost of Generating Funds</b>					
Fundraising Costs		211,523	-	211,523	232,958
<b>Charitable Activities</b>					
Research		530,025	672	530,697	589,034
Education & Awareness		130,725	15,929	146,654	119,964
Governance		32,568	-	32,568	24,628
<b>Total Resources Expended</b>	2	<b>904,841</b>	<b>16,601</b>	<b>921,442</b>	<b>966,584</b>
<b>Net Income / (Expenditure)</b>		<b>379,986</b>		<b>379,986</b>	<b>328,825</b>
<b>Total Funds Brought Forward</b>		<b>1,604,420</b>	<b>-</b>	<b>1,604,420</b>	<b>1,275,595</b>
<b>Total Funds Carried Forward</b>		<b>1,984,406</b>	<b>-</b>	<b>1,984,406</b>	<b>1,604,420</b>

There were no recognised gains or losses other than those shown in the above statement of financial activities. The results for the above financial periods derive from continuing operations.

**THE ORCHID CANCER APPEAL**

**BALANCE SHEET**

As at 30 June 2008

	Notes	2008		2007	
		£	£	£	£
<b>FIXED ASSETS</b>					
Tangible Assets	6		1,994		2,991
<b>CURRENT ASSETS</b>					
Cash at Bank and in Hand		3,059,604		2,916,736	
Other debtors	7	<u>119,942</u>		<u>81,561</u>	
		3,179,546		2,998,297	
<b>CREDITORS</b>					
Amount falling due within one year	8	<u>694,271</u>		<u>913,590</u>	
<b>NET CURRENT ASSETS</b>			<u>2,485,275</u>		<u>2,084,707</u>
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>			2,487,269		2,087,698
<b>CREDITORS</b>					
Amount falling in greater than one year	9		502,863		483,278
<b>NET ASSETS</b>			<u>1,984,406</u>		<u>1,604,420</u>
<b>REPRESENTED BY</b>					
Accumulated Funds					
Restricted Funds	10	-			-
Designated Funds	10	1,625,000		1,345,000	
General Unrestricted Funds	10	<u>359,406</u>		<u>259,420</u>	
			<u>1,984,406</u>		<u>1,604,420</u>
			<u>1,984,406</u>		<u>1,604,420</u>

The company is limited by guarantee.

The accounts have been prepared in accordance with the special provisions of Part VII of the Companies Act 1985 relating to small companies.

The financial statements were approved by the Board and authorised for issue on 8 December 2008 and signed on its behalf by:



Mr R J O Barton



Mr R S Broadhurst

# THE ORCHID CANCER APPEAL

## NOTES TO THE FINANCIAL STATEMENTS

For the year ended 30 June 2008

---

### 1. ACCOUNTING POLICIES

The accounts have been prepared under the historical cost convention and in accordance with the Statement of Recommended Practice "Accounting and Reporting by Charities" SORP 2005, the Companies Act 1985 and applicable accounting standards in the United Kingdom. A summary of the more important accounting policies, which have been applied consistently, is set out below.

#### Cash Flow

The accounts do not include a cash flow statement because the charity, as a small reporting entity, is exempt from the requirement to prepare such a statement under Financial Reporting Standards 1 'Cash Flow Statements.'

#### Taxation

No corporation tax is provided for, as the company, being a charity, is exempt. Due to its current activities the charity is not registered for VAT and therefore cannot recover VAT on its expenses.

#### Depreciation

Depreciation is provided at the following annual rates so as to write off the cost of each asset over its useful life. Assets with a purchase consideration in excess of £1,000 are capitalised.

Computer and Office Equipment	33 1/3% on written down value
-------------------------------	-------------------------------

#### Funds Accounting

General funds are unrestricted funds available for use at the discretion of the Trustees in furtherance of the general activities of the charity and which have not been designated for other purposes.

Designated funds comprise funds which have been set aside at the discretion of the Trustees for specific purposes.

Restricted funds are funds subject to specific restrictions imposed by donors or by the nature of the appeal. The purpose and use of their restricted funds is set out in the notes to the financial statements.

#### Incoming Resources

All incoming resources becoming available to the company during the year are included when there is entitlement to the income, certainty of receipt and amounts can be measured with sufficient reliability.

#### Resources Expended

Cost of generating funds includes costs associated with the fund-raising events in furtherance of the charity's objects.

Charitable Expenditure includes costs associated with particular activities in furtherance of the charity's objects.

Governance costs are those incurred in connection with the management of the charity's assets, organisational administration, and compliance with constitutional and statutory requirements.

Charitable expenditure and governance costs comprise direct expenditure including direct staff costs attributable to the activity. Support costs which cannot be directly attributed to an activity have been allocated to activities on a basis consistent with use of the resources.

Grants payable are charged in the year when the offer is conveyed to the recipient except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are fulfilled. Grants offered subject to conditions which have not been met at the year-end are noted as a commitment, but not accrued as expenditure.

#### Pension Scheme

The charity operates a defined contribution stakeholder pension scheme. The amount charged to the statement of financial activities in respect of pension costs is the charity's contributions payable in the year. The assets of the scheme are held separately from the charity. There was no outstanding liability owed to the scheme at the end of the current or prior years.

# THE ORCHID CANCER APPEAL

## NOTES TO THE FINANCIAL STATEMENTS

For the year ended 30 June 2008

### 2. TOTAL RESOURCES EXPENDED

	Cost of generating funds	Research	Education & Awareness	Governance	2008	2007
	£	£	£	£	£	£
Grants	-	489,591	-	-	489,591	551,410
Fundraising expenses	107,160	-	-	-	107,160	117,417
Information	-	-	29,530	-	29,530	34,520
Education & awareness	-	-	17,371	-	17,371	21,522
Audit fees	-	-	-	4,739	4,739	4,471
Other	-	-	-	1,711	1,711	2,279
	107,160	489,591	46,901	6,450	650,102	731,619
<i>Support costs</i>						
Staff costs	81,895	32,255	78,274	20,494	212,918	193,953
Depreciation	383	151	367	96	997	1,495
Other	22,085	8,700	21,112	5,528	57,425	39,517
	104,363	41,106	99,753	26,118	271,340	234,965
Total resources expended	211,523	530,697	146,654	32,568	921,442	966,584

No trustee received any remuneration during the period (2007: nil). Three trustees received reimbursement of expenses of £1,499 (2007: one - £3,518).

### 3. GRANTS AWARDED

	2008	2007
	£	£
Grant commitments brought forward	1,373,474	1,850,847
Institutional grants for medical research awarded during year	502,863	551,410
Net write back of grants	(13,272)	-
Payments made during year	(710,669)	(1,028,783)
Grant commitments carried forward	1,152,396	1,373,474
Payable less than one year	649,533	890,196
Payable two to five years	502,863	483,278

### 4. TAXATION

Orchid is a registered charity and as such its income and gains are exempt from corporation tax to the extent that they are applied to its charitable objectives. There is no corporation tax charge for the year.

# THE ORCHID CANCER APPEAL

## NOTES TO THE FINANCIAL STATEMENTS

For the year ended 30 June 2008

### 5. EMPLOYEES

The average number of employees during the year was 6 (2007: 3)

	2008	2007
	£	£
Wages and Salaries	192,360	175,100
Social Security Costs	20,558	18,853
Employer pension costs	546	-
Total staff costs	<u>213,464</u>	<u>193,953</u>

One (2007: one) employee earned £70,000-£80,000 (2007: £70,000-£80,000) during the period.

### 6. TANGIBLE ASSETS

	Computer and Office Equipment	
	2008	2007
	£	£
<b>COST</b>		
At 1 July 2007	15,692	15,692
Additions	-	-
At 30 June 2008	<u>15,692</u>	<u>15,692</u>
<b>DEPRECIATION</b>		
At 1 July 2007	12,701	11,206
Charge for the period	997	1,495
At 30 June 2008	<u>13,698</u>	<u>12,701</u>
<b>NET BOOK VALUE</b>		
At 30 June 2008 /2007	<u>1,994</u>	<u>2,991</u>

### 7. DEBTORS

	2008	2007
	£	£
Prepayments	59,696	29,883
Other debtors and accrued income	<u>60,246</u>	<u>51,678</u>
	<u>119,942</u>	<u>81,561</u>

**THE ORCHID CANCER APPEAL**

**NOTES TO THE FINANCIAL STATEMENTS**

For the year ended 30 June 2008

**8. LIABILITIES: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	2008	2007
	£	£
Grants payable	649,533	890,196
Other Creditors	36,440	3,586
Taxation and Social Security	328	12,472
Accruals	7,970	7,336
	<u>694,271</u>	<u>913,590</u>

**9. LIABILITIES: AMOUNTS FALLING DUE IN GREATER THAN ONE YEAR**

	2008	2007
	£	£
Grants payable	502,863	483,278
	<u>502,863</u>	<u>483,278</u>

**10. FUNDS**

	Brought Forward	Income	Expenditure	Transfers	Carried forward
	£	£	£	£	£
<b>Unrestricted</b>					
General	259,420	1,284,827	904,841	(280,000)	359,406
Designated – Research	1,000,000	-	-	250,000	1,250,000
Designated – Development	225,000	-	-	-	225,000
Designated – Awareness	120,000	-	-	30,000	150,000
	<u>1,604,420</u>	<u>1,284,827</u>	<u>904,841</u>	<u>-</u>	<u>1,984,406</u>
<b>Restricted</b>					
Research	-	672	672	-	-
Information Dissemination	-	15,929	15,929	-	-
	<u>-</u>	<u>16,601</u>	<u>16,601</u>	<u>-</u>	<u>-</u>
<b>Total Restricted</b>	<u>-</u>	<u>16,601</u>	<u>16,601</u>	<u>-</u>	<u>-</u>
<b>Total Funds</b>	<u>1,604,420</u>	<u>1,301,428</u>	<u>921,442</u>	<u>-</u>	<u>1,984,406</u>

# THE ORCHID CANCER APPEAL

## NOTES TO THE FINANCIAL STATEMENTS

For the year ended 30 June 2008

### 10. FUNDS (continued)

General funds are unrestricted funds available for use at the discretion of the Trustees in furtherance of the general activities of the charity and which have not been designated for other purposes.

Designated Research fund represent monies set aside at the Trustees' discretion to be used to help fund the costs of research programmes in the future.

Designated Development funds represent monies set aside at the Trustees' discretion to be used to help fund the costs related to increasing the organisational capacity of the charity.

Designated Awareness funds represent monies set aside at the Trustees' discretion to be used to help fund specific awareness activities.

Restricted funds represent monies specifically raised to fund specific research programmes or information dissemination and have been fully expended in the period.

### 11. RELATED PARTY TRANSACTIONS

There were no related parties during the year.

### AMOUNTS HELD FOR THIRD PARTIES

During the year the charity has worked with the Prostate Cancer Charter for Action and has been administering funds on its behalf. Orchid Cancer Appeal has no powers to make payments from these funds except as directed by the Charter's Steering Group

	£
Balance held at 1st July 2007	2,436
Funds received in the year	-
Disbursements made	<u>2,436</u>
<b>Balance held at 30th June 2008</b>	<b><u>-</u></b>

### 12. LEASE COMMITMENTS

At 30 June 2008, the charity had annual commitments under operating leases, as set out below:

Other Operating leases that expire within:	2008	2007
	£	£
1 Year	<u>-</u>	<u>5,053</u>
	<u>-</u>	<u>5,053</u>